Page 4 - Synlogic Inc News Today

27.09.2023 - CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) - Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced ... Seite 1

/PRNewswire/ -- The urea cycle disorder treatment market size is expected to grow by USD 235.5 million from 2022 to 2027. In addition, the momentum of the...

Synlogic, Inc. (NASDAQ:SYBX – Get Free Report) saw a significant drop in short interest in the month of August. As of August 15th, there was short interest totalling 259,100 shares, a drop of 22.4% from the July 31st total of 333,700 shares. Based on an average daily volume of 203,200 shares, the short-interest ratio is […]

Gainers

Chardan Capital reiterated their buy rating on shares of Synlogic (NASDAQ:SYBX – Free Report) in a research report released on Friday morning, Benzinga reports. Chardan Capital currently has a $6.00 price objective on the biotechnology company’s stock. Separately, HC Wainwright restated a buy rating and set a $5.00 target price on shares of Synlogic in […]

Chardan Capital reaffirmed their buy rating on shares of Synlogic (NASDAQ:SYBX – Free Report) in a research report sent to investors on Friday, Benzinga reports. The brokerage currently has a $6.00 price objective on the biotechnology company’s stock. Separately, HC Wainwright reiterated a buy rating and set a $5.00 price target on shares of Synlogic […]

10.08.2023 - Recent milestones include initiation of the pivotal Phase 3 trial, Synpheny-3, and receipt of Fast Track designation for labafenogene marselecobac as a potential treatment for PKUCAMBRIDGE, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) - Synlogic, Inc. ...

Daiichi Sankyo (OTCMKTS:DSNKY – Get Free Report) and Roche (OTCMKTS:RHHVF – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership. Analyst Recommendations This is a breakdown of current ratings […]

Daiichi Sankyo (OTCMKTS:DSNKY – Get Free Report) and Roche (OTCMKTS:RHHVF – Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, institutional ownership and risk. Profitability This table compares Daiichi Sankyo and Roche’s net […]

Global Human Microbiome Therapeutics Market 2023-2027. The human microbiome therapeutics market is forecasted to grow by USD 732.95 mn during 2022-2027,...